About fACE: Peri-Operative Use of ACE Inhibitors
Since the introduction of the first Angiotensin-converting enzyme inhibitor (ACEI) captopril in 1981, ACE inhibitors have become a mainstay of anti-hypertensive therapy. In addition to lowering BP, there is overwhelming evidence that ACE inhibitors (and angiotensin-receptor blockers (ARB)) provide end organ protection independent of blood their pressure lowering properties in diseases such as CHF, post MI, diabetes, and renal insufficiency.1 It is an unresolved issue, however, if ACE inhibitors have a protective or deleterious effect on perioperative outcomes2.(SELECT FULL TEXT TO CONTINUE)
- Received June 6, 2012.
- Accepted June 8, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited